Navigation Links
Promising new West Nile therapy cures disease in mice

West Nile virus alarmed Americans when it made its first U.S. appearance in New York City in 1999. It has since spread from coast to coast, sickened more than 16,000 Americans and killed more than 600. As the virus spread, medical investigators hastened research to develop an effective vaccine or therapy. None currently exist, but a newly published paper by researchers at Washington University in St. Louis points to a promising treatment. This research, published today online by Nature Medicine, was funded in part by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The research team developed an infection-fighting antibody that mimics one produced by people whose immune systems successfully fend off the West Nile virus. The researchers tested their antibody in mice and say its success warrants further development and testing in people with West Nile disease.

"West Nile virus has emerged in the United States as a regular seasonal threat, particularly for people over 50. We currently do not have a proven therapy for people with serious West Nile disease, so we will continue to aggressively pursue all promising leads for an effective treatment," says Anthony S. Fauci, M.D., director of NIAID.

Scientists do not know why some people infected with West Nile virus have no symptoms or a mild flu-like illness, while in others the virus invades the central nervous system and causes paralysis or coma. "We could give this antibody to mice as long as five days after infection, when West Nile virus had entered the brain, and it could still cure them," says Washington University senior investigator Michael Diamond, M.D., Ph.D., who headed the research team, which is supported in part by the NIAID-funded Midwest Regional Center of Excellence for Biodefense and Emerging Infectious Diseases. "It also completely protected the mice against death."

The researchers decided to develop the potential
'"/>

Source:NIH


Page: 1 2

Related biology news :

1. Another Look Finds Promising Proteomics Test is Not Biologically Plausible
2. Promising therapies for haemophilia & heart disease
3. Promising cell protein may play role in infection and dry eye
4. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
5. Columbia research lifts major hurdle to gene therapy for cancer
6. Combination therapy boosts effectiveness of telomere-directed cancer cell death
7. Gene therapy converts dead bone graft to new, living tissue
8. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
9. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
10. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
11. New therapy for HIV/AIDS eliminates needles and excessive toxicity
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Promising new West Nile therapy cures disease mice

(Date:7/11/2014)... There is evidence that under the normal ... and development, maintain neuronal environment, and exhibit ... and neurodegenerative disease. Previous studies have found ... cells after chemical induction have reduced viability, ... application. Prof. Xiaodong Yuan, Kailuan General Hospital, ...
(Date:7/11/2014)... Rio de Janeiro, Brazil- In the brains of ... mechanism that allows an electric or chemical signal ... another. Chemical synapses, which are the most abundant ... inhibitory. Synapse formation is crucial for learning, memory, ... and inhibitory synapses critical for brain function. ...
(Date:7/10/2014)... , June 30, 2014  Aware, Inc. (NASDAQ: ... and services, previously announced on June 26, 2014 that ... dividend of $1.75 per share, or approximately $40 million ... July 10, 2014 and a payment date of July ... that it had set an ex-dividend date for this ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
... ... survey conducted by WCS scientists, supported by the U.S. Agency for ... gray wolves, markhor goats, and leopard cats are surviving in parts ... camera-trap surveys, transect surveys, and DNA identification of scat samples in ...
... disorder that disrupts memory, thought and behavior, is devastating ... Alzheimer,s Association, one in eight Americans over the age ... University has discovered that an everyday spice in your ... An extract found in cinnamon bark, called ...
... Two of the world,s leading research universities have ... research and create a framework for a biofuels ... of Queensland, Australia, jointly will pursue means of ... and commercialization, and further development and commercialization in ...
Cached Biology News:Wildlife surviving conflict in Afghanistan 2Wildlife surviving conflict in Afghanistan 3Alzheimer's prevention in your pantry 2Clemson University and the University of Queensland form biofuels research partnership 2Clemson University and the University of Queensland form biofuels research partnership 3
(Date:7/11/2014)... , July 11, 2014  Researchers have ... three-dimensional images. The new technology, called Virtual Finger, ... small structures like neurons and synapses using the ... unique technology makes 3D imaging studies orders of ... at an unprecedented level across many areas of ...
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Terascala, the ... announced that Alan Swahn, a former vice president of ... team as vice president of marketing. Terascala’s software when ... and NetApp create the highest performance and most reliable ... appointed to guide Terascala’s channel expansion and broaden its ...
(Date:7/10/2014)... 10, 2014 OMICS Group’s 5th International ... 18-20 August, 2014 at Double Tree by Hilton Beijing, ... developments in Analytical & Bioanalytical research methods only to ... on this occasion, Dr. Srinubabu Gedela, MD of OMICS ... is a remarkable one in bringing a unique and ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... Nutriments, the makers of Apocaps®, the world,s first dietary ... federal grant to research the application of its apoptosis-inducing ... part of the U.S. government,s $1 Billion Qualifying Therapeutic ... the U.S. Department of Health and Human Services. The ...
... THIRD QUARTER ENDED SEPTEMBER 30, 2010 ... ... lpUnit=,PRN,; --> ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
... ... ... var shortURL = ""; BitlyCB.alertResponse = function(data) ... first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key in first_result) { ...
Cached Biology Technology:Functional Nutriments Awarded Federal Grant to Apply Its Dog Nutraceutical Research to Human Cancer 2ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 2ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 3ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 4ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 5ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 6ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 7ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 8ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 9ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 10ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 11ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 12ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 13ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 14ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 15ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 16ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 17ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 18ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 19ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 20ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 21ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 22ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 23ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 24ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 25ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 26ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 27ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 28ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 29ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 30ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 31ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 32ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 33Oncothyreon Reports Third Quarter 2010 Financial Results 2Oncothyreon Reports Third Quarter 2010 Financial Results 3
EDTA, disodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99.0-101.0%, nuclease-free.Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemi...
Mycoplasma tested...
Alkaline Phosphatase Stabilizer Solution, 1 L...
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
Biology Products: